|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MRPS10 |
Gene summary for MRPS10 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MRPS10 | Gene ID | 55173 |
| Gene name | mitochondrial ribosomal protein S10 | |
| Gene Alias | MRP-S10 | |
| Cytomap | 6p21.1 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | A0A024RD03 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55173 | MRPS10 | LZE2T | Human | Esophagus | ESCC | 9.48e-08 | 1.62e+00 | 0.082 |
| 55173 | MRPS10 | LZE4T | Human | Esophagus | ESCC | 6.25e-18 | 6.73e-01 | 0.0811 |
| 55173 | MRPS10 | LZE5T | Human | Esophagus | ESCC | 9.94e-05 | 5.38e-01 | 0.0514 |
| 55173 | MRPS10 | LZE7T | Human | Esophagus | ESCC | 5.25e-05 | 4.00e-01 | 0.0667 |
| 55173 | MRPS10 | LZE8T | Human | Esophagus | ESCC | 3.85e-07 | 3.97e-01 | 0.067 |
| 55173 | MRPS10 | LZE20T | Human | Esophagus | ESCC | 3.27e-08 | 4.93e-01 | 0.0662 |
| 55173 | MRPS10 | LZE22T | Human | Esophagus | ESCC | 1.66e-03 | 7.25e-01 | 0.068 |
| 55173 | MRPS10 | LZE24T | Human | Esophagus | ESCC | 2.53e-17 | 5.37e-01 | 0.0596 |
| 55173 | MRPS10 | LZE21T | Human | Esophagus | ESCC | 1.32e-03 | 2.52e-01 | 0.0655 |
| 55173 | MRPS10 | LZE6T | Human | Esophagus | ESCC | 7.69e-10 | 5.82e-01 | 0.0845 |
| 55173 | MRPS10 | P1T-E | Human | Esophagus | ESCC | 2.75e-09 | 5.64e-01 | 0.0875 |
| 55173 | MRPS10 | P2T-E | Human | Esophagus | ESCC | 2.16e-46 | 8.21e-01 | 0.1177 |
| 55173 | MRPS10 | P4T-E | Human | Esophagus | ESCC | 6.24e-38 | 1.06e+00 | 0.1323 |
| 55173 | MRPS10 | P5T-E | Human | Esophagus | ESCC | 1.05e-39 | 7.91e-01 | 0.1327 |
| 55173 | MRPS10 | P8T-E | Human | Esophagus | ESCC | 1.05e-22 | 3.74e-01 | 0.0889 |
| 55173 | MRPS10 | P9T-E | Human | Esophagus | ESCC | 4.79e-16 | 4.55e-01 | 0.1131 |
| 55173 | MRPS10 | P10T-E | Human | Esophagus | ESCC | 1.72e-21 | 4.52e-01 | 0.116 |
| 55173 | MRPS10 | P11T-E | Human | Esophagus | ESCC | 1.66e-22 | 9.25e-01 | 0.1426 |
| 55173 | MRPS10 | P12T-E | Human | Esophagus | ESCC | 8.86e-30 | 5.65e-01 | 0.1122 |
| 55173 | MRPS10 | P15T-E | Human | Esophagus | ESCC | 1.13e-20 | 5.17e-01 | 0.1149 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa03010211 | Esophagus | ESCC | Ribosome | 129/4205 | 167/8465 | 1.43e-13 | 3.43e-12 | 1.75e-12 | 129 |
| hsa03010310 | Esophagus | ESCC | Ribosome | 129/4205 | 167/8465 | 1.43e-13 | 3.43e-12 | 1.75e-12 | 129 |
| hsa0301022 | Liver | Cirrhotic | Ribosome | 127/2530 | 167/8465 | 2.12e-35 | 7.06e-33 | 4.35e-33 | 127 |
| hsa0301032 | Liver | Cirrhotic | Ribosome | 127/2530 | 167/8465 | 2.12e-35 | 7.06e-33 | 4.35e-33 | 127 |
| hsa0301042 | Liver | HCC | Ribosome | 128/4020 | 167/8465 | 7.32e-15 | 2.23e-13 | 1.24e-13 | 128 |
| hsa0301052 | Liver | HCC | Ribosome | 128/4020 | 167/8465 | 7.32e-15 | 2.23e-13 | 1.24e-13 | 128 |
| hsa0301030 | Oral cavity | OSCC | Ribosome | 128/3704 | 167/8465 | 2.42e-18 | 1.62e-16 | 8.25e-17 | 128 |
| hsa03010114 | Oral cavity | OSCC | Ribosome | 128/3704 | 167/8465 | 2.42e-18 | 1.62e-16 | 8.25e-17 | 128 |
| hsa03010210 | Oral cavity | LP | Ribosome | 127/2418 | 167/8465 | 1.22e-37 | 4.05e-35 | 2.61e-35 | 127 |
| hsa0301038 | Oral cavity | LP | Ribosome | 127/2418 | 167/8465 | 1.22e-37 | 4.05e-35 | 2.61e-35 | 127 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MRPS10 | SNV | Missense_Mutation | c.174G>C | p.Leu58Phe | p.L58F | P82664 | protein_coding | tolerated(0.06) | benign(0.034) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| MRPS10 | SNV | Missense_Mutation | c.136N>A | p.Gln46Lys | p.Q46K | P82664 | protein_coding | tolerated(0.11) | benign(0.024) | TCGA-D8-A1X9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD | |
| MRPS10 | insertion | Nonsense_Mutation | novel | c.76_77insAGAGTTTGCCCTAAACTGTGGCAAACTGGG | p.Ser26delinsTer | p.S26delins* | P82664 | protein_coding | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| MRPS10 | SNV | Missense_Mutation | rs756763607 | c.524N>G | p.Thr175Arg | p.T175R | P82664 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| MRPS10 | insertion | In_Frame_Ins | rs746229043 | c.525_526insACT | p.Thr175dup | p.T175dup | P82664 | protein_coding | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD | ||
| MRPS10 | SNV | Missense_Mutation | c.247N>T | p.His83Tyr | p.H83Y | P82664 | protein_coding | deleterious(0.01) | probably_damaging(0.978) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MRPS10 | SNV | Missense_Mutation | c.244N>T | p.Gly82Cys | p.G82C | P82664 | protein_coding | deleterious(0.01) | benign(0.376) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MRPS10 | SNV | Missense_Mutation | rs754001754 | c.562N>G | p.Ile188Val | p.I188V | P82664 | protein_coding | tolerated(1) | benign(0.001) | TCGA-AJ-A2QM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR |
| MRPS10 | SNV | Missense_Mutation | novel | c.158N>G | p.Asp53Gly | p.D53G | P82664 | protein_coding | tolerated(0.15) | benign(0.185) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MRPS10 | SNV | Missense_Mutation | novel | c.112C>A | p.Leu38Ile | p.L38I | P82664 | protein_coding | tolerated(0.16) | benign(0.201) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |